ArticleCase reports in medicine2026
Remarkable Response to Immunotherapy and VEGFR Inhibitor in Xp11 Translocation Renal Cell Carcinoma in a 17-Year-Old Adolescent.
Article in Case reports in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Remarkable Response to Immunotherapy and VEGFR Inhibitor in Xp11 Translocation Renal Cell Carcinoma in a 17-Year-Old Adolescent.Case reports in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Xp11 translocation renal cell carcinoma (tRCC) is a rare and aggressive renal cancer characterized by gene fusion involving Objective: To report the clinical presentation, molecular diagnosis, and therapeutic response of an adolescent patient with metastatic Xp11 tRCC treated with pembrolizumab and lenvatinib. Methods: A 17-year-old female presented with a large left renal mass, gross hematuria, extensive metastases to the supraclavicular, mediastinal, and intra-abdominal lymph nodes, and pleural nodules. Immunohistochemistry confirmed transcription factor E3 (TFE3) positivity, and next-generation sequencing identified an Results: The patient showed rapid clinical improvement, with her Eastern Cooperative Oncology Group Performance Status Scale grade improving from 3 to 1 after the initial cycles. CT imaging after the sixth cycle demonstrated a marked reduction in the size of the primary tumor and in the sizes and numbers of metastatic lesions, involved lymph nodes, and pleural nodules. The patient recovered to normal well-being. Conclusion: Pembrolizumab combined with lenvatinib showed significant antitumor activity in an adolescent with advanced
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.